The most frequent site of osteoarthritis (OA) in the forefoot is in the first metatarsophalangeal (MTP) joint, which is reported to affect one in 45 Americans over the age of 50. First MTP OA often presents with pain and limited range of motion due to the development of osteophytes on the dorsal aspect of the metatarsal head and the proximal phalanx. Patients complain of pain with push off and an inability to wear shoes, which can force the hallux into dorsiflexion. First MTP OA is characterized by a limitation in range of motion, which can progress from a functional limitation of motion to differing degrees of degenerative OA.
Cartiva SCI is used in the treatment of patients with degenerative and post-traumatic osteoarthritis of the first MTP joint. Cartiva SCI is implanted in the metatarsal head, where its placement allows for addressing focal articular defects without requiring the removal of a patient’s healthy tissue or replacement of the opposing articular surface. The Cartiva implant is intended to provide surgeons with an alternative to arthrodesis, which limits a patient’s future mobility and shoe wear options. The Cartiva procedure preserves more bone, maintains motion in the joint, reduces rehabilitation time and enables patients to return to normal activity sooner than with fusion. Also, the procedure burns no bridges such that in the case of implant failure, the implant can easily be converted to a fusion.
Our unique cartilage replacement technology can revolutionize the way you approach OA of the first MTP joint by offering your patients an alternative that:
For more information see Cartiva® foot products
Download a copy of the
surgical technique (PDF)